HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer
Despite the demonstrated clinical benefits in breast cancer, diverse systemic and organ-specific adverse events, including dose-limiting toxicities, have been reported even at suboptimal therapeutic doses and pose significant barriers to pursuing dose escalations for maximizing therapeutic efficacy.
Authors
- Cristina Naranjo Ortiz
- Mridula George (ORCID: https://orcid.org/0000-0003-2013-4017)
- Seohyuk Lee (ORCID: https://orcid.org/0000-0003-3023-1304)
- Adriana Kahn (ORCID: https://orcid.org/0000-0002-5306-0571)
- Mariya Rozenblit (ORCID: https://orcid.org/0000-0003-0244-429X)
- Maryam B. Lustberg (ORCID: https://orcid.org/0000-0001-8559-5645)
Institutions
- Rutgers, The State University of New Jersey (US)
- Beth Israel Deaconess Medical Center (US)
- Yale Cancer Center (US)
- Yale University (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/cam4.71415
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00